Results 161 to 170 of about 8,846,713 (318)

Low-profile metasurface-backed wideband antenna array for mm-wave applications. [PDF]

Sci Rep
Kiani SH, Rafique U, Shoaib N, Abbasi MI, Elmannai H, Ibrahim MI, Dalarsson M.   +6 more
europepmc   +1 more source

Low-Profile Reactor [PDF]

Chemical & Engineering News Archive, 2012
openaire   +1 more source

Fenton, M.H.R., discusses butter, Maribyrnong, Vic. [picture] /

, 1915
Title from inscription bot.
Low, David, 1891-1963.
core  

Circulating tumor cell viability during and after radiotherapy mirrors treatment response in cancer patients

Molecular Oncology, EarlyView.
Radiotherapy (RT) response depends on the DNA repair capacity of tumor and host cells. We show that circulating tumor cell (CTC) counts and apoptosis rates before and after RT predict treatment response and outcome, which can be accessed via easily accessible liquid biopsy approaches. Created in BioRender. Wikman, H.
Yvonne Goy, Jana Löptien, Cornelia Coith, Afroditi Nanou, Katharina Hintelmann, Pinnschmidt Hans, Cordula Petersen, Klaus Pantel, Sabine Riethdorf, Kerstin Borgmann, Harriet Wikman   +10 more
wiley   +1 more source

High-gain and low-profile antenna using novel reflective surface for satellite applications. [PDF]

PLoS One
Nguyen LN.
europepmc   +1 more source

J.G. Appell [i.e. Appel], Q. [picture] /

, 1915
Title from inscription l.r.; Percy Deane Collection.; Reproduced in: Caricatures by Low ...
Low, David, 1891-1963.
core  

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

W. Elliot Johnson, M.H.R. [picture] /

, 1915
Title from inscription bot.c.; Percy Deane Collection.; Reroduced in: Caricatures by Low ...
Low, David, 1891-1963.
core  

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Case Report: Low-profile covered stents in CHD: the role of Gore Viabahn (VBX) stents. [PDF]

Front Pediatr
Rebonato M, Almeida C, Pilati M, Piccinelli E, Butera G.   +4 more
europepmc   +1 more source